Novartis Investigative Site

Trondheim NO-7011

0 studies enrolling now · 9 studies all time

What they study most

Acute Leukemias, Atherosclerosis, Cardiovascular Disease, Chronic Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes Mellitus and Heart Failure, Multiple Myeloma, Myelogenous Leukemia, Chronic, Symptomatic Refractory Resistant Carcinoid Disease, Type 2 Diabetes Mellitus

Studies at this site

• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) — Completed
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early
• Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease — Completed
• A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) — Completed